PR90893

HANGZHOU, China, July 28, 2021 /PRNewswire=KYODO JBN/ --

On July 27, 2021, Venus Medtech (Hangzhou) Inc. ("Venus Medtech") (stock code:

2500.HK), a leading provider of comprehensive interventional heart valve

therapy solutions in China, and its controlling subsidiary Renaly Ltd.,

announced that Professor Martin B. Leon, MD, a pioneer in the field of

interventional cardiovascular devices, has been appointed as the Global

Principal Investigator (PI) for its new-generation renal artery denervation

(RDN) system.

Dr. Leon is currently Professor of Medicine at Columbia University Irving

Medical Center (CUIMC) in New York. He is also Director of the Center for

Interventional Vascular Therapy (CIVT), Director of the Cardiac Catheterization

Laboratories and the Director of the executive board of the New

York-Presbyterian University Hospital of Columbia and Cornell Heart & Valve

Center. In addition, he is the founder and Chairman of the annual Transcatheter

Cardiovascular Therapeutics (TCT) conference. As a leader in the field of

cardiovascular interventions, Dr. Leon has participated in more than 50

clinical trials in his role as PI, and performed more than 10,000 operations.

In the field of RDN, Dr. Leon and his team have served as the PI in clinical

trials for several innovative systems including Medtronic's Symplicity Spyral™

Renal Denervation System and ReCor Medical's Paradise™ Ultrasonic Denervation

System, both of which were awarded Breakthrough Device Designation by the U.S

Food and Drug Administration (FDA) in 2020.

The new-generation RDN system was developed by Renaly, the controlling

subsidiary of Venus Medtech. Its exclusive Dual-Mode Ultrasound Technology

(DMUT) Platform can achieve noncontact continuous ablation treatment with

real-time ultrasound imaging, significantly reducing the occurrence of various

issues such as insufficient nerve ablation or vascular damage caused by

uncontrolled ablation. The delivery of accurate and efficient ablation shifts

the treatment paradigm to more predictable outcomes and simplifies the

procedure flow, ultimately enhancing the procedure's safety and efficacy.

Hypertension is one of the world's most common chronic diseases. About

one-third of the adult population worldwide suffers from hypertension[1]. The

number of people diagnosed with hypertension in China exceeds 330 million,

ranking the country first worldwide in terms of the number of sufferers of the

condition. Data from the China Hypertension Survey shows that the prevalence

rate of hypertension among adults over 18 years of age was 27.9% at the time

of the survey (2012-2015), and has since continued trending upward. It is a

contributor in 50% and 20% of cardiovascular disease morbidity and mortality

respectively in China. Hypertension, independent risk factor of cardiovascular

events, can lead to complications such as stroke, myocardial infarction, heart

failure, renal insufficiency, as a result, the control and treatment of

hypertension is beneficial in that it can decrease the risk of cardiovascular

complications[2].

Dr. Leon said: "I'm delighted to be appointed the PI of Renaly's new-generation

RDN system. Hypertension is one of the major risk factors for cardiovascular

disease. The development of RDN therapy presents a novel and promising

therapeutic option for patients with resistant hypertension and poor adherence

to medication. Addressing the clinical pain points of incomplete or excessive

ablation associated with first-generation systems, Renaly's ultrasound-based

renal denervation system is expected to significantly improve safety and

controllability by realizing even and controllable ablation while using

real-time ultrasound imaging. We are looking forward to starting clinical

trials as soon as possible."

Eric Zi, Founder, Executive Director and Managing Director of Venus Medtech

said: "We will focus on developing new devices and procedures, bionics, image

fusion technology and digital sensing in terms of our future medical technology

portfolio, all of which we plan to deeply integrate with our therapeutic

products. By doing so, we can provide a line-up of solutions that covers the

entire therapeutic process end-to-end, encompassing the procedure itself as

well as the pre-op and post-op portions of the treatment. Renaly can be seen as

a model for how one can integrate new procedures and imaging, by combining

image recognition navigation with ultrasound to provide an optimized

technology-based therapy to hypertensive patients. We are pleased to welcome

Dr. Leon as our Global Principal Investigator. This is not our first

collaboration as he has been a member of our Global Advisory Board and plays a

leading role in promoting technological innovation and product globalization.

We believe that with Dr. Leon's rich experience in the field, the innovative

RDN system will rapidly advance through clinical trials and deliver benefits to

patients worldwide."

Reference

[1]. World Health Organization Report: A global brief on hypertension – silent

killer, global public health crisis.

[2]. Chinese Circulation Journal, September, 2020, Vol. 35 No.9 (Serial No.267)

SOURCE  Venus Medtech (Hangzhou) Inc.

Image Attachments Links:

   Link: http://asianetnews.net/view-attachment?attach-id=397373

   Caption: Venus Medtech (Hangzhou) Inc.